Cancer Targeted Therapy & Drug Trial Pipeline Simulator

Microscopic Tissue Kinetics (2D)

Cancer Target

Healthy Cells

Drug Particles

PK/PD Plasma Concentration & Therapeutic Window

24h Kinetics

Molecular Target Tuning & Dosing

Dosage Level: 12 mg/kg

Target Affinity (Kd): 4.2 nM

Off-Target Cross Affinity: 180 nM

Clearance Half-Life: 36 hrs

Cancer Clearance 92.0%

Healthy Viability 96.0%

Therapeutic Index 42.8

Clinical Trial Attrition Pipeline

Phase III Passed

Phase I: Safety & Toxicity 88.0% Pass Systemic Off-Target Toxicity within Safety Threshold

Phase II: Target Efficacy 79.0% Pass Sustained Tumor Clearance > MEC Window

Phase III: Randomized RCT 72.0% Pass Statistically Significant Superiority vs Standard of Care

Clinical Insight: Candidate molecule balances potent oncogenic target suppression with negligible healthy mucosal/marrow cytotoxicity, establishing a broad therapeutic safety window.